{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:33:57Z","timestamp":1793237637880,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["SMOG15-CE17-009-01"],"award-info":[{"award-number":["SMOG15-CE17-009-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["SMOG15-CE17-009-01"],"award-info":[{"award-number":["SMOG15-CE17-009-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["SMOG15-CE17-009-01"],"award-info":[{"award-number":["SMOG15-CE17-009-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["SMOG15-CE17-009-01"],"award-info":[{"award-number":["SMOG15-CE17-009-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ecole Doctorale Environnement-Sant\u00e9, Dijon, France"},{"DOI":"10.13039\/501100004618","name":"Universit\u00e9 de Bourgogne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011773","name":"Conseil r\u00e9gional de Bourgogne-Franche-Comt\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011773","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Bourguignonne de Cardiologie"},{"name":"Centre Hospitalier Universitaire de Dijon, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Growth\/differentiation factor-15 (GDF15) is considered an unfavourable prognostic biomarker for cardiovascular disease in clinical data, while experimental studies suggest it has cardioprotective potential. This study focuses on the direct cardiac effects of GDF15 during ischemia\u2013reperfusion injury in Wistar male rats, employing concentrations relevant to patients at high cardiovascular risk. Initially, we examined circulating levels and heart tissue expression of GDF15 in rats subjected to ischemia\u2013reperfusion and sham operations in vivo. We then evaluated the cardiac effects of GDF15 both in vivo and ex vivo, administering recombinant GDF15 either before 30 min of ischemia (preconditioning) or at the onset of reperfusion (postconditioning). We compared infarct size and cardiac contractile recovery between control and rGDF15-treated rats. Contrary to our expectations, ischemia\u2013reperfusion did not increase GDF15 plasma levels compared to sham-operated rats. However, cardiac protein and mRNA expression increased in the infarcted zone of the ischemic heart after 24 h of reperfusion. Notably, preconditioning with rGDF15 had a cardioprotective effect, reducing infarct size both in vivo (65\u2009\u00b1\u20095% in control vs. 42\u2009\u00b1\u20096% in rGDF15 groups) and ex vivo (60\u2009\u00b1\u20094% in control vs. 45\u2009\u00b1\u20094% in rGDF15 groups), while enhancing cardiac contractile recovery ex vivo. However, postconditioning with rGDF15 did not alter infarct size or the recovery of contractile parameters in vivo or ex vivo. These novel findings reveal that the short-term exogenous administration of rGDF15 before ischemia, at physiologically relevant levels, protects the heart against ischemia\u2013reperfusion injury in both in vivo and ex vivo settings. The ex vivo results indicate that rGDF15 operates independently of the inflammatory, endocrine and nervous systems, suggesting direct and potent cardioprotective properties against ischemia\u2013reperfusion injury.<\/jats:p>","DOI":"10.1038\/s41598-024-63880-5","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:02:56Z","timestamp":1717599776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Growth\/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration"],"prefix":"10.1038","volume":"14","author":[{"given":"Geoffrey","family":"Dogon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Rigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Potel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Bejot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"63880_CR1","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U. S. A. 94, 11514\u201311519. https:\/\/doi.org\/10.1073\/pnas.94.21.11514 (1997).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"63880_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/jir.2009.0052","volume":"30","author":"AR Bauskin","year":"2010","unstructured":"Bauskin, A. R. et al. The TGF-beta superfamily cytokine MIC-1\/GDF15: Secretory mechanisms facilitate creation of latent stromal stores. J. Interferon Cytokine Res. 30, 389\u2013397. https:\/\/doi.org\/10.1089\/jir.2009.0052 (2010).","journal-title":"J. Interferon Cytokine Res."},{"key":"63880_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 23, 1215\u20131219. https:\/\/doi.org\/10.1038\/nm.4393 (2017).","journal-title":"Nat. Med."},{"key":"63880_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255\u2013259. https:\/\/doi.org\/10.1038\/nature24042 (2017).","journal-title":"Nature"},{"key":"63880_CR5","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150\u20131157. https:\/\/doi.org\/10.1038\/nm.4392 (2017).","journal-title":"Nat. Med."},{"key":"63880_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158\u20131166. https:\/\/doi.org\/10.1038\/nm.4394 (2017).","journal-title":"Nat. Med."},{"key":"63880_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.tem.2020.10.004","volume":"31","author":"L Rochette","year":"2020","unstructured":"Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Insights into mechanisms of GDF15 and receptor GFRAL: Therapeutic targets. Trends Endocrinol. Metab. 31, 939\u2013951. https:\/\/doi.org\/10.1016\/j.tem.2020.10.004 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"63880_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12872-020-01744-2","volume":"20","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: Two-sample Mendelian randomization study. BMC Cardiovasc. Disord. 20, 462. https:\/\/doi.org\/10.1186\/s12872-020-01744-2 (2020).","journal-title":"BMC Cardiovasc. Disord."},{"key":"63880_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/1354750X.2011.580006","volume":"16","author":"X Xu","year":"2011","unstructured":"Xu, X., Li, Z. & Gao, W. Growth differentiation factor 15 in cardiovascular diseases: From bench to bedside. Biomarkers 16, 466\u2013475. https:\/\/doi.org\/10.3109\/1354750X.2011.580006 (2011).","journal-title":"Biomarkers"},{"key":"63880_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s00059-009-3317-3","volume":"34","author":"T Kempf","year":"2009","unstructured":"Kempf, T. & Wollert, K. C. Growth differentiation factor-15: A new biomarker in cardiovascular disease. Herz 34, 594\u2013599. https:\/\/doi.org\/10.1007\/s00059-009-3317-3 (2009).","journal-title":"Herz"},{"key":"63880_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1474-9726.2010.00629.x","volume":"9","author":"FE Wiklund","year":"2010","unstructured":"Wiklund, F. E. et al. Macrophage inhibitory cytokine-1 (MIC-1\/GDF15): A new marker of all-cause mortality. Aging Cell 9, 1057\u20131064. https:\/\/doi.org\/10.1111\/j.1474-9726.2010.00629.x (2010).","journal-title":"Aging Cell"},{"key":"63880_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/eurheartj\/ehac577","volume":"44","author":"ET Kato","year":"2023","unstructured":"Kato, E. T. et al. Growth differentiation factor 15 and cardiovascular risk: Individual patient meta-analysis. Eur. Heart J. 44, 293\u2013300. https:\/\/doi.org\/10.1093\/eurheartj\/ehac577 (2023).","journal-title":"Eur. Heart J."},{"key":"63880_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1373\/clinchem.2012.201210","volume":"59","author":"KM Eggers","year":"2013","unstructured":"Eggers, K. M., Kempf, T., Wallentin, L., Wollert, K. C. & Lind, L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin. Chem. 59, 1091\u20131098. https:\/\/doi.org\/10.1373\/clinchem.2012.201210 (2013).","journal-title":"Clin. Chem."},{"key":"63880_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140\u2013151. https:\/\/doi.org\/10.1373\/clinchem.2016.255174 (2017).","journal-title":"Clin. Chem."},{"key":"63880_CR15","doi-asserted-by":"publisher","first-page":"E452","DOI":"10.1532\/hsf.2355","volume":"23","author":"J Zhou","year":"2020","unstructured":"Zhou, J., Kang, Z., Liu, L., Guo, Y. & Chen, S. Predicting value of growth differentiation factor 15 and its correlations with atrial fibrillation. Heart Surg. Forum 23, E452\u2013E460. https:\/\/doi.org\/10.1532\/hsf.2355 (2020).","journal-title":"Heart Surg. Forum"},{"key":"63880_CR16","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","volume":"130","author":"L Wallentin","year":"2014","unstructured":"Wallentin, L. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130, 1847\u20131858. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011204 (2014).","journal-title":"Circulation"},{"key":"63880_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1253\/circj.CJ-23-0088","volume":"87","author":"Y Otaki","year":"2023","unstructured":"Otaki, Y. et al. Growth differentiation factor 15 and clinical outcomes in Japanese patients with heart failure. Circ. J. 87, 1120\u20131129. https:\/\/doi.org\/10.1253\/circj.CJ-23-0088 (2023).","journal-title":"Circ. J."},{"key":"63880_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf, T. et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054\u20131060. https:\/\/doi.org\/10.1016\/j.jacc.2007.04.091 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"63880_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1373\/clinchem.2011.171926","volume":"58","author":"A Rohatgi","year":"2012","unstructured":"Rohatgi, A. et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: Observations from the Dallas Heart Study. Clin. Chem. 58, 172\u2013182. https:\/\/doi.org\/10.1373\/clinchem.2011.171926 (2012).","journal-title":"Clin. Chem."},{"key":"63880_CR20","doi-asserted-by":"publisher","first-page":"1054187","DOI":"10.3389\/fcvm.2023.1054187","volume":"10","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: A meta-analysis and systematic review. Front. Cardiovasc. Med. 10, 1054187. https:\/\/doi.org\/10.3389\/fcvm.2023.1054187 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"63880_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/eurheartj\/ehn600","volume":"30","author":"SQ Khan","year":"2009","unstructured":"Khan, S. Q. et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur. Heart J. 30, 1057\u20131065. https:\/\/doi.org\/10.1093\/eurheartj\/ehn600 (2009).","journal-title":"Eur. Heart J."},{"key":"63880_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12933-016-0375-8","volume":"15","author":"S Farhan","year":"2016","unstructured":"Farhan, S. et al. Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study. Cardiovasc. Diabetol. 15, 60. https:\/\/doi.org\/10.1186\/s12933-016-0375-8 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"63880_CR23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/eurheartj\/ehv491","volume":"37","author":"E Hagstrom","year":"2016","unstructured":"Hagstrom, E. et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: Results from the PLATO study. Eur. Heart J. 37, 1325\u20131333. https:\/\/doi.org\/10.1093\/eurheartj\/ehv491 (2016).","journal-title":"Eur. Heart J."},{"key":"63880_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","volume":"31","author":"MP Bonaca","year":"2011","unstructured":"Bonaca, M. P. et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: Observations from PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Biol. 31, 203\u2013210. https:\/\/doi.org\/10.1161\/ATVBAHA.110.213512 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"63880_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.RES.0000202805.73038.48","volume":"98","author":"T Kempf","year":"2006","unstructured":"Kempf, T. et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia\/reperfusion injury. Circ. Res. 98, 351\u2013360. https:\/\/doi.org\/10.1161\/01.RES.0000202805.73038.48 (2006).","journal-title":"Circ. Res."},{"key":"63880_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurjhf\/hfs120","volume":"14","author":"SI Lok","year":"2012","unstructured":"Lok, S. I. et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur. J. Heart Fail. 14, 1249\u20131256. https:\/\/doi.org\/10.1093\/eurjhf\/hfs120 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"63880_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jchf.2014.06.013","volume":"3","author":"T Ahmad","year":"2015","unstructured":"Ahmad, T. et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 3, 30\u201339. https:\/\/doi.org\/10.1016\/j.jchf.2014.06.013 (2015).","journal-title":"JACC Heart Fail."},{"key":"63880_CR28","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1161\/STROKEAHA.118.022207","volume":"49","author":"A Meloux","year":"2018","unstructured":"Meloux, A. et al. Ischemic stroke increases heart vulnerability to ischemia-reperfusion and alters myocardial cardioprotective pathways. Stroke 49, 2752\u20132760. https:\/\/doi.org\/10.1161\/STROKEAHA.118.022207 (2018).","journal-title":"Stroke"},{"key":"63880_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/01.RES.0000202804.84885.d0","volume":"98","author":"J Xu","year":"2006","unstructured":"Xu, J. et al. GDF15\/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res. 98, 342\u2013350. https:\/\/doi.org\/10.1161\/01.RES.0000202804.84885.d0 (2006).","journal-title":"Circ. Res."},{"key":"63880_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jcp.22102","volume":"224","author":"J Heger","year":"2010","unstructured":"Heger, J. et al. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J. Cell. Physiol. 224, 120\u2013126. https:\/\/doi.org\/10.1002\/jcp.22102 (2010).","journal-title":"J. Cell. Physiol."},{"key":"63880_CR31","doi-asserted-by":"publisher","first-page":"36531","DOI":"10.18632\/oncotarget.16607","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Over-expression of growth differentiation factor 15 (GDF15) preventing cold ischemia reperfusion (I\/R) injury in heart transplantation through Foxo3a signaling. Oncotarget 8, 36531\u201336544. https:\/\/doi.org\/10.18632\/oncotarget.16607 (2017).","journal-title":"Oncotarget"},{"key":"63880_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.2354","volume":"17","author":"T Kempf","year":"2011","unstructured":"Kempf, T. et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 17, 581\u2013588. https:\/\/doi.org\/10.1038\/nm.2354 (2011).","journal-title":"Nat. Med."},{"key":"63880_CR33","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3389\/fimmu.2018.02407","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. GDF15 regulates Malat-1 circular RNA and inactivates NF\u03baB signaling leading to immune tolerogenic DCs for preventing alloimmune rejection in heart transplantation. Front. Immunol. 9, 2407. https:\/\/doi.org\/10.3389\/fimmu.2018.02407 (2018).","journal-title":"Front. Immunol."},{"key":"63880_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fneur.2019.00611","volume":"10","author":"C Breniere","year":"2019","unstructured":"Breniere, C. et al. Growth differentiation factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. Front. Neurol. 10, 611. https:\/\/doi.org\/10.3389\/fneur.2019.00611 (2019).","journal-title":"Front. Neurol."},{"key":"63880_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.26502\/fccm.92920174","volume":"4","author":"A Meloux","year":"2020","unstructured":"Meloux, A. et al. Association between growth differentiation factor-15 and heart failure complicating acute myocardial infarction. Cardiol. Cardiovasc. Med. 4, 773\u2013789 (2020).","journal-title":"Cardiol. Cardiovasc. Med."},{"key":"63880_CR36","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1161\/CIRCRESAHA.118.313859","volume":"123","author":"HR Lieder","year":"2018","unstructured":"Lieder, H. R. et al. Vago-splenic axis in signal transduction of remote ischemic preconditioning in pigs and rats. Circ. Res. 123, 1152\u20131163. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313859 (2018).","journal-title":"Circ. Res."},{"key":"63880_CR37","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/bloodadvances.2019000375","volume":"3","author":"S Hao","year":"2019","unstructured":"Hao, S. et al. Gdf15 regulates murine stress erythroid progenitor proliferation and the development of the stress erythropoiesis niche. Blood Adv. 3, 2205\u20132217. https:\/\/doi.org\/10.1182\/bloodadvances.2019000375 (2019).","journal-title":"Blood Adv."},{"key":"63880_CR38","doi-asserted-by":"publisher","first-page":"14520","DOI":"10.1038\/s41598-022-18572-3","volume":"12","author":"K Haraguchi-Suzuki","year":"2022","unstructured":"Haraguchi-Suzuki, K. et al. Local anesthetic lidocaine-inducible gene, growth differentiation factor-15 suppresses the growth of cancer cell lines. Sci. Rep. 12, 14520. https:\/\/doi.org\/10.1038\/s41598-022-18572-3 (2022).","journal-title":"Sci. Rep."},{"key":"63880_CR39","doi-asserted-by":"publisher","first-page":"e105759","DOI":"10.1371\/journal.pone.0105759","volume":"9","author":"A Kahli","year":"2014","unstructured":"Kahli, A. et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. PloS One 9, e105759. https:\/\/doi.org\/10.1371\/journal.pone.0105759 (2014).","journal-title":"PloS One"},{"key":"63880_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.jvca.2015.01.023","volume":"29","author":"O Bouchot","year":"2015","unstructured":"Bouchot, O. et al. Low circulating levels of growth differentiation factor-15 before coronary artery bypass surgery may predict postoperative atrial fibrillation. J. Cardiothorac. Vasc. Anesth. 29, 1131\u20131139. https:\/\/doi.org\/10.1053\/j.jvca.2015.01.023 (2015).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"63880_CR41","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3892\/mmr.2015.4573","volume":"13","author":"M Zhang","year":"2016","unstructured":"Zhang, M. et al. Growth differentiation factor 15 may protect the myocardium from no-reflow by inhibiting the inflammatory-like response that predominantly involves neutrophil infiltration. Mol. Med. Rep. 13, 623\u2013632. https:\/\/doi.org\/10.3892\/mmr.2015.4573 (2016).","journal-title":"Mol. Med. Rep."},{"key":"63880_CR42","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1161\/CIRCRESAHA.114.302653","volume":"114","author":"PP Rainer","year":"2014","unstructured":"Rainer, P. P. et al. Cardiomyocyte-specific transforming growth factor beta suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ. Res. 114, 1246\u20131257. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302653 (2014).","journal-title":"Circ. Res."},{"key":"63880_CR43","doi-asserted-by":"publisher","first-page":"e0187349","DOI":"10.1371\/journal.pone.0187349","volume":"12","author":"OE Olsen","year":"2017","unstructured":"Olsen, O. E., Skjaervik, A., Stordal, B. F., Sundan, A. & Holien, T. TGF-beta contamination of purified recombinant GDF15. PloS One 12, e0187349. https:\/\/doi.org\/10.1371\/journal.pone.0187349 (2017).","journal-title":"PloS One"},{"key":"63880_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VWW Tsai","year":"2018","unstructured":"Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353\u2013368. https:\/\/doi.org\/10.1016\/j.cmet.2018.07.018 (2018).","journal-title":"Cell Metab."},{"key":"63880_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.molmed.2017.10.005","volume":"23","author":"SN Breit","year":"2017","unstructured":"Breit, S. N., Tsai, V. W. & Brown, D. A. Targeting obesity and cachexia: Identification of the GFRAL receptor-MIC-1\/GDF15 pathway. Trends Mol. Med. 23, 1065\u20131067. https:\/\/doi.org\/10.1016\/j.molmed.2017.10.005 (2017).","journal-title":"Trends Mol. Med."},{"key":"63880_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","volume":"122","author":"S Sciarretta","year":"2018","unstructured":"Sciarretta, S., Forte, M., Frati, G. & Sadoshima, J. New insights into the role of mTOR signaling in the cardiovascular system. Circ. Res. 122, 489\u2013505. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311147 (2018).","journal-title":"Circ. Res."},{"key":"63880_CR47","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s10495-006-6305-6","volume":"11","author":"DY Li","year":"2006","unstructured":"Li, D. Y. et al. Role of ERK1\/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 11, 923\u2013930. https:\/\/doi.org\/10.1007\/s10495-006-6305-6 (2006).","journal-title":"Apoptosis"},{"key":"63880_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00395-023-00992-5","volume":"118","author":"DM Yellon","year":"2023","unstructured":"Yellon, D. M., Beikoghli Kalkhoran, S. & Davidson, S. M. The RISK pathway leading to mitochondria and cardioprotection: How everything started. Basic Res. Cardiol. 118, 22. https:\/\/doi.org\/10.1007\/s00395-023-00992-5 (2023).","journal-title":"Basic Res. Cardiol."},{"key":"63880_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.apsb.2019.01.010","volume":"9","author":"J Song","year":"2019","unstructured":"Song, J. et al. Inhibition of FOXO3a\/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia\/reperfusion injury. Acta Pharm. Sin. B 9, 505\u2013515. https:\/\/doi.org\/10.1016\/j.apsb.2019.01.010 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"63880_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41419-018-0358-7","volume":"9","author":"Y Xie","year":"2018","unstructured":"Xie, Y. et al. Ischemic preconditioning attenuates ischemia\/reperfusion-induced kidney injury by activating autophagy via the SGK1 signaling pathway. Cell Death Dis. 9, 338. https:\/\/doi.org\/10.1038\/s41419-018-0358-7 (2018).","journal-title":"Cell Death Dis."},{"key":"63880_CR51","doi-asserted-by":"publisher","first-page":"H1365","DOI":"10.1152\/ajpheart.01005.2007","volume":"294","author":"B Juhasz","year":"2008","unstructured":"Juhasz, B. et al. Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt\/FOXO pathway in rat myocardium. Am. J. Physiol. Heart Circ. Physiol. 294, H1365-1370. https:\/\/doi.org\/10.1152\/ajpheart.01005.2007 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"63880_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.yexmp.2013.08.003","volume":"95","author":"XF Qi","year":"2013","unstructured":"Qi, X. F. et al. Involvement of the FoxO3a pathway in the ischemia\/reperfusion injury of cardiac microvascular endothelial cells. Exp. Mol. Pathol. 95, 242\u2013247. https:\/\/doi.org\/10.1016\/j.yexmp.2013.08.003 (2013).","journal-title":"Exp. Mol. Pathol."},{"key":"63880_CR53","doi-asserted-by":"publisher","first-page":"H962","DOI":"10.1152\/ajpheart.2001.280.3.H962","volume":"280","author":"SB Haudek","year":"2001","unstructured":"Haudek, S. B. et al. Overexpression of cardiac I-\u03baB\u03b1 prevents endotoxin-induced myocardial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 280, H962\u2013H968. https:\/\/doi.org\/10.1152\/ajpheart.2001.280.3.H962 (2001).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"63880_CR54","doi-asserted-by":"publisher","first-page":"H1089","DOI":"10.1152\/ajpheart.00067.2013","volume":"305","author":"XQ Zhang","year":"2013","unstructured":"Zhang, X. Q. et al. Cardiomyocyte-specific p65 NF-kappaB deletion protects the injured heart by preservation of calcium handling. Am. J. Physiol. Heart Circ. Physiol. 305, H1089-1097. https:\/\/doi.org\/10.1152\/ajpheart.00067.2013 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"63880_CR55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(12)60916-7","volume":"381","author":"G Heusch","year":"2013","unstructured":"Heusch, G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet 381, 166\u2013175. https:\/\/doi.org\/10.1016\/S0140-6736(12)60916-7 (2013).","journal-title":"Lancet"},{"key":"63880_CR56","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.3390\/ijms22052519","volume":"22","author":"S Roth","year":"2021","unstructured":"Roth, S. et al. Pharmacological conditioning of the heart: An update on experimental developments and clinical implications. Int. J. Mol. Sci. 22, 2519. https:\/\/doi.org\/10.3390\/ijms22052519 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"63880_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/bja\/aei155","volume":"95","author":"E Lucchinetti","year":"2005","unstructured":"Lucchinetti, E., da Silva, R., Pasch, T., Schaub, M. C. & Zaugg, M. Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: Evidence of opposing genomic responses in cardioprotection by pre- and postconditioning. Br. J. Anaesth. 95, 140\u2013152. https:\/\/doi.org\/10.1093\/bja\/aei155 (2005).","journal-title":"Br. J. Anaesth."},{"key":"63880_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1213\/ANE.0000000000003450","volume":"127","author":"J Heiberg","year":"2018","unstructured":"Heiberg, J., Royse, C. F., Royse, A. G. & Andrews, D. T. Propofol attenuates the myocardial protection properties of desflurane by modulating mitochondrial permeability transition. Anesth. Analg. 127, 387\u2013397. https:\/\/doi.org\/10.1213\/ANE.0000000000003450 (2018).","journal-title":"Anesth. Analg."},{"key":"63880_CR59","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1139\/cjpp-2013-0048","volume":"91","author":"OM Duicu","year":"2013","unstructured":"Duicu, O. M., Angoulvant, D. & Muntean, D. M. Cardioprotection against myocardial reperfusion injury: Successes, failures, and perspectives. Can. J. Physiol. Pharmacol. 91, 657\u2013662. https:\/\/doi.org\/10.1139\/cjpp-2013-0048 (2013).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"63880_CR60","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jtcvs.2008.07.041","volume":"136","author":"NC Moss","year":"2008","unstructured":"Moss, N. C. et al. Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J. Thorac. Cardiovasc. Surg. 136, 1274\u20131279. https:\/\/doi.org\/10.1016\/j.jtcvs.2008.07.041 (2008).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"63880_CR61","doi-asserted-by":"publisher","first-page":"H530","DOI":"10.1152\/ajpheart.00549.2006","volume":"292","author":"Y Onai","year":"2007","unstructured":"Onai, Y. et al. Inhibition of NF-kappaB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 292, H530-538. https:\/\/doi.org\/10.1152\/ajpheart.00549.2006 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"63880_CR62","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00395-021-00893-5","volume":"116","author":"S Lecour","year":"2021","unstructured":"Lecour, S. et al. IMproving preclinical assessment of cardioprotective therapies (IMPACT) criteria: Guidelines of the EU-CARDIOPROTECTION COST action. Basic Res. Cardiol. 116, 52. https:\/\/doi.org\/10.1007\/s00395-021-00893-5 (2021).","journal-title":"Basic Res. Cardiol."},{"key":"63880_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2018.09.086","volume":"73","author":"SM Davidson","year":"2019","unstructured":"Davidson, S. M. et al. Multitarget strategies to reduce myocardial ischemia\/reperfusion injury: JACC review topic of the week. J. Am. Coll. Cardiol. 73, 89\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.086 (2019).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63880-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63880-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63880-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:30:02Z","timestamp":1717601402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63880-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["63880"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-63880-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12949"}}